🇺🇸 FDA
Pipeline program

JR-141, Elaprase 2 mg/ml concentrate for solution for infusion

JR-141-GS31

Phase 3 small_molecule active

Quick answer

JR-141, Elaprase 2 mg/ml concentrate for solution for infusion for Mucopolysaccharidosis type II, Hunter Syndrome is a Phase 3 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Mucopolysaccharidosis type II, Hunter Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials